glp-1 adoption Impact of Drug on Consumer Food Demand GLP-1 Analogues Market Size to

In the field of weight loss drug development, the recently disclosed clinical data of Amgens weight loss candidate drug Maridebart Cafraglutide (referred to as MariTide, formerly known as AMG 133) has drawn widespread attention in the industry and is considered a potential Game Changer. The reason why MariTide is seen as a game-changer in the weight loss drug market dominated by Wegovy and Zepbound is an important factor: MariTides molecular modality is a unique antibody-peptide conjugate (also known as Peptibody)

"The most important one is just the weight loss and therefore less stress on the spine

[DOI] [PMC free article] [PubMed] [Google Scholar] 18.Kabahizi A., Wallace B., Lieu L., Chau D., Dong Y., Hwang E.S., et al

doi: 10.1038/969 61 SkovJ.DejgaardA.FrokiaerJ.HolstJ